Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) SVP Mark Brosius sold 2,128 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total value of $1,095,920.00. Following the transaction, the senior vice president now owns 273 shares in the company, valued at $140,595. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Mark Brosius also recently made the following trade(s):
- On Thursday, October 24th, Mark Brosius sold 22 shares of Intuitive Surgical stock. The shares were sold at an average price of $510.79, for a total value of $11,237.38.
- On Thursday, September 12th, Mark Brosius sold 2,115 shares of Intuitive Surgical stock. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65.
Intuitive Surgical Stock Performance
Shares of ISRG traded down $0.95 on Thursday, reaching $511.63. The stock had a trading volume of 755,379 shares, compared to its average volume of 1,471,841. The firm has a market capitalization of $181.48 billion, a price-to-earnings ratio of 92.35, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. The company has a 50-day simple moving average of $486.71 and a 200-day simple moving average of $440.96. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $523.34.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several research firms recently issued reports on ISRG. Mizuho raised their price target on Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Leerink Partners raised their price target on Intuitive Surgical from $489.00 to $502.00 in a research report on Thursday, October 17th. Citigroup raised their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Barclays raised their price target on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Finally, Truist Financial increased their price objective on Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.
About Intuitive Surgical
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
Read More
- Five stocks we like better than Intuitive Surgical
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- The 3 Best Fintech Stocks to Buy Now
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.